{"nctId":"NCT01485887","briefTitle":"Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)","startDateStruct":{"date":"2012-01"},"conditions":["Major Depressive Disorder"],"count":50,"armGroups":[{"label":"Venlafaxine ER","type":"EXPERIMENTAL","interventionNames":["Drug: Venlafaxine ER"]}],"interventions":[{"name":"Venlafaxine ER","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Outpatients who have completed 8 weeks double-blind study (B2411263), without major protocol violations or tolerability concerns in the opinion of the investigator.\n\nExclusion Criteria:\n\n* Clinically important abnormalities on baseline (Week 8 of the double-blind study) physical examination, or any unresolved clinically significant abnormalities on electrocardiogram (ECG), laboratory test results, or vital signs recorded before Week 8 in the previous double-blind study.\n* Significant risk of suicide based on clinical judgment.\n* Use of prohibited treatments","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"Any untoward medical occurrence in a participant who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events: those which occurred or worsened after baseline. An AE resulting in any of the following outcomes, was considered to be a serious adverse event: death; lifethreatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Clinical Significant Vital Changes","description":"Clinical significant changes were pre-defined for systolic blood pressure (SBP), diastolic blood pressure (DBP) , and pulse rate (PR). An average value of 3 measurements in each visit meeting the following criteria for 3 consecutive visits was determined as clinical siginificant changes: DBP \\>= 90 mmHg with change from the baseline \\>= 10 mmHg; SBP \\>= 140 mmHg with change from the baseline \\>= 20 mmHg; PR \\>= 100 bpm with change from the baseline \\>= 15 bpm.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Clinical Significant Laboratory Tests Changes","description":"Clinical significant changes were pre-defined for each laboratory test based on the criteria: Red Blood Cell Count \\<0.8 x lower limit normal (LLN); Lymphocytes (%) \\<0.8 x LLN; Eosinophils (%) \\>1.2 x upper limit normal (ULN); Total Bilirubin \\>1.5 x ULN; Alanine Aminotransferase (ALT) \\>3.0 x ULN; Gamma glutamyl transferase (GGT) \\>3.0 x ULN; Uric Acid \\>1.2 x ULN; Cholesterol \\>1.3 x ULN; Low density lipoprotein (LDL) cholesterol \\>1.2 x ULN; Triglycerides \\>1.3 x ULN; Glucose \\>1.5 x ULN; Urine Glucose \\[qualitative (Qual)\\] \\>=1; Urine Protein (Qual) \\>=1; Urine Blood/Hemoglobin (Hgb) (Qual) \\>=1.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Clinical Significant Electrocardiogram (ECG) Changes","description":"Clinically significant ECG findings included: corrected QT (QTc), QT interval corrected using the Bazett's formula (QTcB), and QT interval corrected using the Fridericia formula (QTcF)\\> 450 millisecond (ms), \\>480 ms, and \\>500 ms respsctively, change from baseline in QTc, QTcB, and QTcF \\>= 30 ms, and \\>= 60 ms, respectively.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With no at Baseline and Yes at Any Post Baseline for Columbia Suicide-Severity Rating Scale (C-SSRS) According to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories","description":"C-SSRS is a participant rated questionnaire to assess suicidal ideation, suicidal behavior, actual attempts (yes or no responses), and intensity of ideation (rated 1=low severity to 5=high severity). Yes/No responses are mapped to Columbia Classification Algorithm of Suicide Assessment (C-CASA) categories: Completed suicide, suicide attempt, preparatory acts toward imminent suicidal behavior, suicidal ideation, and self-injurious behavior, or no suicidal intent. A participant could have a yes or no response in more than one category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 17-item Hamilton Rating Scale for Depression (HAM-D17) at Each Post Baseline Time Point","description":"HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, work and activities, sleep, suicide, psychomotor agitation/retardation, appetite, sexual interest, anxiety, and somatic symptoms). The items of the HAM-D17 are rated on a scale of 0 to 2 (8 items) or 0 to 4 (9 items), and the total score ranges from 0 to 52. Higher scores indicate more severe symptoms. Change from baseline: mean score at observation minus mean score at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"2.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"3.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"4.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"4.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"4.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"4.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"5.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"7.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.2","spread":"4.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.7","spread":"5.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","spread":"5.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.4","spread":"5.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":"5.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.4","spread":"6.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.1","spread":"5.98"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression - Severity (CGI-S) at Each Post Baseline Time Point","description":"CGI-S is a 7-point clinician rated scale to assess severity of participant's current illness state; range: 1=normal, not ill at all, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill patients. Higher scores reflect higher severity of current illness states. Change from baseline: mean score at observation minus mean score at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"0.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"1.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"1.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"1.12"}]}]}]},{"type":"SECONDARY","title":"Mean Clinical Global Impression - Improvement (CGI-I) Score at Each Post Baseline Time Point","description":"CGI-I is a 7-point clinician rated scale ranging from 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, to 7=very much worse. Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Scores above 4 reflect worsening of illness state as compared to baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"0.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"0.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"1.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"0.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"1.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"1.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"1.15"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 16-item Quick Inventory of Depressive Symptomatology Self-Report Japanese Version (QIDS16-SR-J) at Each Post Baseline Time Point","description":"QIDS16-SR-J is a self-rated scale used in patients with major depressive disorder to measure the overall severity of depressive symptoms: 1) sad mood; 2) concentration; 3) self-criticism; 4) suicidal ideation; 5) interest; 6) energy/fatigue; 7) sleep disturbance (initial, middle, and late insomnia or hypersomnia); 8) decrease/increase in appetite/weight; and 9) psychomotor agitation/retardation. QIDS16-SR-J items are rated on a scale of 0 to 3, and the total score ranges from 0 to 27. Higher scores indicate more severe symptoms. Change from baseline: mean score at observation minus mean score at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"4.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"4.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"4.73"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":50},"commonTop":["Nasopharyngitis","Headache","Dizziness","Somnolence","Constipation"]}}}